ÂÜÀòÂÒÂ×

Ray Camahort Ph.D. serves as a Member of the Board of Directors at Obsidian Therapeutics and has held the position of Partner at Novo Holdings since October 2015, where Novo Ventures facilitates significant investments in biotech and medtech companies. With a strong background in both executive and advisory roles, Camahort is also involved with multiple companies, including OnCusp Therapeutics, Clasp Therapeutics, Ray Therapeutics, Anthos Therapeutics, iECURE, and Inspirna, serving primarily as a board member or observer. Educational qualifications include a Postdoctoral fellowship in Stem Cell and Regenerative Medicine from Harvard University and a Ph.D. in Biochemistry and Molecular Biology from The University of Kansas.